Filing Flows › Teva Pharmaceutical Industries (TEVA) › Q3 2026 › vs Q3 2025
Teva Pharmaceutical Industries (TEVA) Q3 2026 vs Q3 2025 (year over year)
Teva Pharmaceutical Industries's revenue fell $85.0M (-2%) from $4.5B in Q3 2025 to $4.4B in Q3 2026. The biggest changes: Sale of goods −$167M (-4%); Other +$63.0M (+52%); Distribution +$15.0M (+4%). Gross margin 55.5% against 51.4% (+4.1 pts).
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 55.5% | 51.4% | +4.1 pts |
| Operating margin | 16.2% | 19.7% | -3.4 pts |
| Net margin | 5.3% | 9.7% | -4.4 pts |
| Free cash flow margin | 2.8% | 5.2% | -2.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Sale of goods | $3.7B | $3.9B | −$167M | -4% |
| Distribution | $421M | $406M | $15.0M | +4% |
| Other | $184M | $121M | $63.0M | +52% |
| Licensing arrangements | $49.0M | $46.0M | $3.0M | +7% |
| Revenue | $4.4B | $4.5B | −$85.0M | -2% |
| Gross profit | $2.4B | $2.3B | $136M | +6% |
| Cost of revenue | $2.0B | $2.2B | −$221M | -10% |
| Operating profit | $714M | $882M | −$168M | -19% |
| Operating expenses | $1.7B | $1.4B | $304M | +21% |
| Pre-tax earnings | $300M | $648M | −$348M | -54% |
| Other expense, net | $414M | $234M | $180M | +77% |
| Research & development | $297M | $256M | $41.0M | +16% |
| Sales & marketing | $709M | $656M | $53.0M | +8% |
| General & admin | $298M | $317M | −$19.0M | -6% |
| Other operating costs | $422M | $193M | $229M | +119% |
| Net earnings | $234M | $434M | −$200M | -46% |
| Income tax | $66.0M | $214M | −$148M | -69% |
| Operating cash sources | $517M | $717M | −$200M | -28% |
| Depreciation & amortization | $245M | $249M | −$4.0M | -2% |
| Share-based compensation | $38.0M | $34.0M | $4.0M | +12% |
| Working capital & other | $276M | $348M | −$72.0M | -21% |
| Operating cash flow | $241M | $369M | −$128M | -35% |
| Free cash flow (OCF − capex) | $121M | $233M | −$112M | -48% |
| Capital expenditures | $120M | $136M | −$16.0M | -12% |
Questions
How much did Teva Pharmaceutical Industries's revenue grow year over year in Q3 2026?
Teva Pharmaceutical Industries's revenue fell $85.0M (-2%) from $4.5B in Q3 2025 to $4.4B in Q3 2026.
What drove Teva Pharmaceutical Industries's revenue change in Q3 2026?
Sale of goods −$167M (-4%); Other +$63.0M (+52%); Distribution +$15.0M (+4%).